FDA Approves Pirtobrutinib for Relapsed/Refractory Mantle Cell Lymphoma
Recommended
FDA Approves Pirtobrutinib for Relapsed/Refractory Mantle Cell Lymphoma
On January 27, 2023, the Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib, a non-covalent BTK inhibitor, for relapsed/refractory mantle cell lymphoma (MCL) after at least 2 lines of systemic therapy, including a BTK inhibitor.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->